- Home
- RBOT vs NRSN Comparison
RBOT vs NRSN Comparison
Compare RBOT & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- NRSN
- Stock Information
- Founded
- RBOT 2014
- NRSN 2017
- Country
- RBOT United States
- NRSN Israel
- Employees
- RBOT N/A
- NRSN N/A
- Industry
- RBOT Medical Specialities
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- NRSN Health Care
- Exchange
- RBOT Nasdaq
- NRSN Nasdaq
- Market Cap
- RBOT 45.8M
- NRSN 50.1M
- IPO Year
- RBOT N/A
- NRSN 2021
- Fundamental
- Price
- RBOT $9.32
- NRSN $1.26
- Analyst Decision
- RBOT Hold
- NRSN Buy
- Analyst Count
- RBOT 1
- NRSN 2
- Target Price
- RBOT $8.50
- NRSN $14.00
- AVG Volume (30 Days)
- RBOT 35.2K
- NRSN 372.0K
- Earning Date
- RBOT 08-12-2025
- NRSN 09-29-2025
- Dividend Yield
- RBOT N/A
- NRSN N/A
- EPS Growth
- RBOT N/A
- NRSN N/A
- EPS
- RBOT N/A
- NRSN N/A
- Revenue
- RBOT N/A
- NRSN N/A
- Revenue This Year
- RBOT N/A
- NRSN N/A
- Revenue Next Year
- RBOT N/A
- NRSN N/A
- P/E Ratio
- RBOT N/A
- NRSN N/A
- Revenue Growth
- RBOT N/A
- NRSN N/A
- 52 Week Low
- RBOT $4.27
- NRSN $0.60
- 52 Week High
- RBOT $19.00
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- RBOT 50.57
- NRSN 33.19
- Support Level
- RBOT $8.69
- NRSN $1.00
- Resistance Level
- RBOT $9.58
- NRSN $1.52
- Average True Range (ATR)
- RBOT 0.94
- NRSN 0.21
- MACD
- RBOT -0.21
- NRSN -0.07
- Stochastic Oscillator
- RBOT 15.63
- NRSN 23.64
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.